Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.72 |
| ▸ | DRD4 | P21917 | 6/20 | 0.72 |
| ▸ | DRD3 | P35462 | 6/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | DRD5 | P21918 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23097703 | 0.86 | DRD2 (0.72) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL20389575 | 0.84 | DRD2 (0.66) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL10664987 | 0.84 | DRD2 (1.00) | DRD2DRD4DRD3SLC6A2SLC6A4 | |
| SCHEMBL14587005 | 0.84 | DRD2 (0.94) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL16559653 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL18699533 | 0.84 | DRD2 (0.65) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL18699418 | 0.83 | DRD2 (0.64) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL13532797 | 0.82 | DRD2 (0.87) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL18699461 | 0.81 | DRD2 (0.62) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL29549434 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9023818-B2 | Pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | GLYCON LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | IMI INTERNATIONAL MEDICAL INNOVATIONS, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CHRISTIAN SAMUEL T | 2011-09-29 | — | — | US | disclosed |
| US-20060189547-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CHRISTIAN SAMUEL T | 2006-08-24 | — | — | US | disclosed |
| US-20030119761-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CHRISTIAN SAMUEL T (US) | 2003-06-26 | — | — | US | disclosed |
| US-4914094-A | CARBOSTYRIC OR BENZOXAZINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226441-A2 | Preparation of pharmaceutical compositions for the treatment of hypoxia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | DRD2 110/4885DRD4 51/4885DRD3 93/4885 |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | DRD2 110/4885DRD4 51/4885DRD3 93/4885 |
| US-20030119761-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CSGALNACT1, DDOST, STT3B | DRD2 694/4885DRD4 729/4885DRD3 774/4885 |
| US-20060189547-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CSGALNACT1, DDOST, STT3B | DRD2 694/4885DRD4 729/4885DRD3 774/4885 |
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | DRD2 694/4885DRD4 729/4885DRD3 774/4885 |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | DRD2 694/4885DRD4 729/4885DRD3 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.